{"id":"W4381612716","doi":"10.1200/jco.22.02746","title":"AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"Sanofi","keywords":"Medicine; Internal medicine; Hazard ratio; Estrogen receptor; Oncology; Breast cancer; Fulvestrant; Cancer; Progression-free survival; Clinical endpoint; Gynecology; Clinical trial; Confidence interval; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00295427,0.0006422275,0.005835458,0.0006215082,0.0001779825,0.00001483389,0.0004394649,0.0003947601,0.0007342779],"category_scores_gemma":[0.00277203,0.0005008311,0.001083877,0.001112128,0.0008647178,0.0004860281,0.0001083346,0.001953861,0.000009822061],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0013531,"about_ca_system_score_gemma":0.002196241,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004184835,"about_ca_topic_score_gemma":0.0002241604,"domain_scores_codex":[0.9897994,0.002852586,0.004720294,0.000728277,0.001040126,0.0008592951],"domain_scores_gemma":[0.9878008,0.005484255,0.003947521,0.000345642,0.001794064,0.0006277651],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7612894,0.006644517,0.01655972,0.00004042702,0.004131047,0.000268298,0.003417411,0.0002068778,0.01367527,0.00006880536,0.0002540489,0.1934442],"study_design_scores_gemma":[0.854488,0.09287938,0.02657403,0.0004284439,0.0008718411,0.0001377923,0.004264681,0.00005968811,0.01758307,0.0003408486,0.00179415,0.0005780667],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893228,0.0006797048,0.0001464532,0.005156471,0.001724456,0.002401203,0.0004414745,0.00007109533,0.00005634491],"genre_scores_gemma":[0.9900919,0.002047231,0.006017632,0.0002918346,0.001098653,0.000213694,0.00003688472,0.000117835,0.00008439898],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1928661,"threshold_uncertainty_score":0.9997444,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08678585079797575,"score_gpt":0.4766479143054478,"score_spread":0.389862063507472,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}